Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR–ABL1-positive acute lymphoblastic leukemia... von Pfeifer, H, Wassmann, B, Bethge, W, Dengler, J, Bornhäuser, M, Stadler, M, Beelen, D, Vucinic, V, Burmeister, T, Stelljes, M, Faul, C, Dreger, P, Kiani, A, Schäfer-Eckart, K, Schwerdtfeger, R, Lange, E, Kubuschok, B, Horst, H A, Gramatzki, M, Brück, P, Serve, H, Hoelzer, D, Gökbuget, N, Ottmann, O G

Volltext

Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B‐cell lymphoma (r/r PMBCL) compared to DLBCL‐NOS: A GLA/DRST registry study von Schubert, M., Ayuk, F. A., Bethge, W., Bonin, M., Vucinic, V., Wagner‐Drouet, E. M., Subklewe, M., Baldus, C. D., Glass, B., Marks, R., Mougiakakos, D., Schroers, R., Stelljes, M., Topp, M. S., Wulf, G., Kröger, N., Dreger, P.

Volltext

First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis von Pouyiourou, M., Meyer, A., Stroux, A., Viardot, A., La Rosée, P., Maschmeyer, G., Kämpfe, D., Kahl, C., Vucinic, V., Monecke, A., Hirt, C., Weber, T., Meissner, J., Witzens-Harig, M., Böttcher, S., Schmalenberg, H., Marks, R., Prange-Krex, G., Kroschinsky, F., Hauf, E., Keller, U., Koch, K., Klapper, W., Herold, M., Scholz, Christian W.

Volltext

Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning von Bill, M, Jentzsch, M, Grimm, J, Schubert, K, Lange, T, Cross, M, Behre, G, Vucinic, V, Pönisch, W, Franke, G-N, Niederwieser, D, Schwind, S

Volltext

STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BENDAMUSTINE, PREDNISONE AND BORTEZOMIB INDUCTION IN MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT von Fricke, S., Wang, S., Holzhey, T., Holzvogt, M., Andrea, M., Vucinic, V., Franke, G., Heyn, S., Hell, S., Schetschorke, B., Jentzsch, M., Schwind, S., Zehrfeld, T., Braunert, L., Edelmann, T., Becker, C., Hoffmann, F., Reifenrath, K., Schwarz, M., Schwarzer, A., Flade, F., Hammerschmidt, D., Scholz, M., Merz, M., Platzbecker, U., Pönisch, W.

Volltext

Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cells von Weiss, R., Fernandez, C. P., Boldt, A., Hoffmann, S., Krauss, S., Bach, E., Kirchberg, J., Kurch, L., Merz, M., Metzeler, K., Herling, C., Jentzsch, M., Schwind, S., Petermann, N., Franz, P., Herling, M., Denecke, T., Sabri, O., Fricke, S., Kluge, R., Sack, U., Franke, G., Koehl, U., Platzbecker, U., Georgi, T., Vucinic, V.

Volltext

An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment von Lavie, D., Johnson, N., Borchmann, P., Herrera, A. F., Avigdor, A., Gasiorowski, R., Gregory, G., Keane, C., Vucinic, V., Bazargan, M., Herishanu, Y., Minuk, L., Tzoran, I., Andreadis, C., Armand, P., Kuruvilla, J., Zinzani, P. L., West, R. Marceau, Pillai, P., Marinello, P., Timmerman, J.

Volltext

Endpoints for clinical trials of sarcoidosis von Baughman, R P, Drent, M, Culver, D A, Grutters, J C, Handa, T, Humbert, M, Judson, M A, Lower, E E, Mana, J, Pereira, C A, Prasse, A, Sulica, R, Valyere, D, Vucinic, V, Wells, A U

Volltext

P1356: PATIENT‐SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRAN... von Jentzsch, M., Bischof, L., Backhaus, D., Brauer, D., Franke, G.‐N., Vucinic, V., Platzbecker, U., Schwind, S.

Volltext

P1313: PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH von Jentzsch, M., Herrmann, L., Bischof, L., Backhaus, D., Brauer, D., Franke, G.‐N., Vucinic, V., Platzbecker, U., Schwind, S.

Volltext

OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS von Dreger, P., Martus, P., Holtick, U., Ayuk, F., Wagner‐Drouet, E. M., Wulf, G., Marks, R., Penack, O., Koenecke, C., von Bonin, M., von Tresckow, B., Stelljes, M., Baldus, C., Vucinic, V., Mougiakakos, D., Topp, M., Wolff, D., Schroers, R., Schmitt, M., Schmitt, T., Lengerke, C., Thomas, S., Beelen, D. W., Bethge, W.

Volltext

P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS von Ussmann, J., Hell, S., Schetschorke, B., Friedrich, G., Pfrepper, C., Schwind, S., Jentzsch, M., Vucinic, V., Herling, M., Platzbecker, U., Franke, G.‐N.

Volltext

P509: CLONAL HEMATOPOIESIS‐ASSOCIATED MUTATIONS AS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION von Bischof, L., Ussmann, J., Brauer, D., Backhaus, D., Herrmann, L., Franke, G.‐N., Vucinic, V., Metzeler, K. H., Platzbecker, U., Schwind, S., Jentzsch, M.

Volltext

P1086: FAVEZELIMAB (ANTI–LAG‐3) AND PEMBROLIZUMAB CO‐BLOCKADE IN ANTI–PD‐1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN‐LABEL PHASE 1/2 STUDY... von Gregory, G., Timmerman, J., Lavie, D., Borchmann, P., Herrera, A. F., Minuk, L., Vucinic, V., Armand, P., Avigdor, A., Gasiorowski, R., Herishanu, Y., Keane, C., Kuruvilla, J., Palcza, J., Pillai, P., Marinello, P., Johnson, N. A.

Volltext

P1087: FAVEZELIMAB (ANTI–LAG‐3) AND PEMBROLIZUMAB CO‐BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD‐1 THERAPY: AN OPEN‐LAB... von Herrera, A. F., Lavie, D., Johnson, N. A., Avigdor, A., Borchmann, P., Andreadis, C., Bazargan, A., Gregory, G., Keane, C., Inna, T., Vucinic, V., Zinzani, P. L., Zhang, H., Pillai, P., Marinello, P., Timmerman, J.

Volltext

P1448: LONG‐TERM SURVIVORS AFTER FAILURE OF CAR‐T CELL THERAPY FOR R/R LARGE B‐CELL LYMPHOMA (LBCL): A GLA/DRST STUDY von Derigs, P., Bethge, W., Holtick, U., Tresckow, B., Ayuk, F., Penack, O., Vucinic, V., Bonin, M., Baldus, C., Mougiakakos, D., Wulf, G., Schnetzke, U., Stelljes, M., Thomas, S., Schroers, R., Kroeger, N., Dreger, P.

Volltext

S287: FACTORS INFLUENCING AUTOLOGOUS LYMPHOCYTE COLLECTIONS FOR CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELLS – THE ROLE OF T‐CELL SENESCENCE von Vucinic, V., Tumewu, T., Brückner, M., Jentzsch, M., Ramdohr, F., Buhmann, R., Remane, Y., Hoffmann, S., Janz, M., Penack, O., Vogtmann, G., Ruschpler, E., Bullinger, L., Keller, U., Cross, M., Schwind, S., Herling, M., Franke, G.‐N., Bach, E., Reinhard, H., Platzbecker, U.

Volltext

Effect of obesity on patient-reported outcomes in sarcoidosis von Gvozdenovic, B. S., Mihailovic-Vucinic, V., Vukovic, M., Lower, E. E., Baughman, R. P., Dudvarski-Ilic, A., Zugic, V., Popevic, S., Videnovic-Ivanov, J., Filipovic, S., Stjepanovic, M., Omcikus, M.

Volltext

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany von Bethge, WA, Martus, P, Schmitt, M, Holtick, U, Subklewe, M, von Tresckow, B, Ayuk, F, Wagner-Drouet, EM, Wulf, G, Marks, R, Penack, O, Schnetzke, U, Koenecke, C, von Bonin, M, Stelljes, M, Glass, B, Baldus, CD, Vucinic, V, Mougiakakos, D, Topp, M, Fante, M, Schroers, R, Bayir, L, Borchmann, P, Buecklein, V, Hasenkamp, J, Hanoun, C, Thomas, S, Beelen, D, Lengerke, C, Kroeger, N, Dreger, P

Volltext

Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplan... von Niederwieser, C., Starke, S., Fischer, L., Krahl, R., Beck, J., Gruhn, B., Ebell, W., Körholz, D., Wößmann, W., Bader, P., Lang, P., Al-Ali, H-K., Cross, M., Eisfeld, A-K., Heyn, S., Vucinic, V., Franke, G-N., Lange, T., Pönisch, W., Behre, G., Christiansen, H.

Volltext